NL301339I2 - L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat - Google Patents

L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat

Info

Publication number
NL301339I2
NL301339I2 NL301339C NL301339C NL301339I2 NL 301339 I2 NL301339 I2 NL 301339I2 NL 301339 C NL301339 C NL 301339C NL 301339 C NL301339 C NL 301339C NL 301339 I2 NL301339 I2 NL 301339I2
Authority
NL
Netherlands
Prior art keywords
seladelpar
lysine
dihydrate
salt
lysine salt
Prior art date
Application number
NL301339C
Other languages
English (en)
Dutch (nl)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NL301339I2 publication Critical patent/NL301339I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NL301339C 2005-09-14 2025-08-13 L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat NL301339I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71713705P 2005-09-14 2005-09-14
PCT/US2006/035617 WO2007033231A2 (en) 2005-09-14 2006-09-13 Novel lysine salts of 4-((phenoxyalkyl) thio)-phenoxyacetic acid derivatives

Publications (1)

Publication Number Publication Date
NL301339I2 true NL301339I2 (nl) 2025-09-16

Family

ID=37865545

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301339C NL301339I2 (nl) 2005-09-14 2025-08-13 L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat

Country Status (28)

Country Link
US (2) US7709682B2 (Direct)
EP (1) EP1937065B1 (Direct)
JP (1) JP5467770B2 (Direct)
KR (5) KR20160079129A (Direct)
CN (1) CN101304656B (Direct)
AR (1) AR058044A1 (Direct)
AU (1) AU2006291006B2 (Direct)
BE (1) BE2025C533I2 (Direct)
BR (1) BRPI0615835B8 (Direct)
CA (1) CA2622722C (Direct)
DK (1) DK1937065T3 (Direct)
ES (1) ES2535427T3 (Direct)
FI (1) FIC20253005I1 (Direct)
FR (1) FR25C1030I2 (Direct)
GT (1) GT200600420A (Direct)
HN (1) HN2006032171A (Direct)
HU (2) HUE025185T2 (Direct)
JO (1) JO3006B1 (Direct)
LT (1) LTC1937065I2 (Direct)
NL (1) NL301339I2 (Direct)
NZ (1) NZ566504A (Direct)
PE (1) PE20070434A1 (Direct)
PL (1) PL1937065T3 (Direct)
PT (1) PT1937065E (Direct)
SI (1) SI1937065T1 (Direct)
TW (1) TWI414510B (Direct)
UY (1) UY29791A1 (Direct)
WO (1) WO2007033231A2 (Direct)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004285849B2 (en) * 2003-09-19 2011-04-28 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1670744B9 (en) * 2003-09-19 2012-09-05 Janssen Pharmaceutica NV 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
US20160016982A1 (en) * 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2531200T (pt) * 2010-02-06 2017-08-24 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
RU2013114390A (ru) 2010-08-31 2014-10-10 СНУ Ар энд ДиБи ФАУНДЕЙШН Применение фетального репрограммирования посредством ppar-дельта-агониста
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
KR20160079124A (ko) 2013-11-20 2016-07-05 사이머베이 쎄라퓨틱스, 인코퍼레이티드 동질접합성 가족성 과콜레스테롤증의 치료
US20160279085A1 (en) * 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US9486428B2 (en) 2014-03-20 2016-11-08 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
NZ724740A (en) * 2014-04-11 2019-11-29 Cymabay Therapeutics Inc Treatment of nafld and nash
CA2951280A1 (en) * 2014-06-26 2015-12-30 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
KR20190018643A (ko) * 2016-05-16 2019-02-25 풀마젠 테라퓨틱스 (애즈마) 리미티드 퀴놀린 유도체의 결정
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US20190076500A1 (en) 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
KR102376794B1 (ko) 2017-09-26 2022-03-18 사이머베이 쎄라퓨틱스, 인코퍼레이티드 담즙정체성 소양증의 치료
US20200155487A1 (en) * 2018-11-16 2020-05-21 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
CN119735532A (zh) * 2019-11-21 2025-04-01 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
SI4225291T1 (sl) 2021-02-01 2024-07-31 CymaBay Therapeutics, Inc., Zdravljenje holangiopatij s seladelparjem
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20250135809A (ko) 2023-01-29 2025-09-15 사이머베이 쎄라퓨틱스, 인코퍼레이티드 요독증성 소양증의 치료
EP4654958A1 (en) 2023-01-29 2025-12-03 CymaBay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
CN118546109A (zh) * 2023-02-24 2024-08-27 哈尔滨三联药业股份有限公司 含氮杂环类化合物及其医药用途
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2026030479A1 (en) * 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Process for making seladelpar
WO2026030533A1 (en) 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Seladelpar for use in treating liver disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3169761D1 (en) 1981-01-09 1985-05-09 Fisons Plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
EP0106565B1 (en) 1982-09-30 1986-09-10 Merck Frosst Canada Inc. Leukotriene antagonists, their production, and compositions containing them
US4820867A (en) 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) * 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
EP0562796A1 (en) * 1992-03-23 1993-09-29 Terumo Kabushiki Kaisha Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
WO1997028115A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Antidiabetic agents
JP2000504021A (ja) 1996-02-02 2000-04-04 メルク エンド カンパニー インコーポレーテッド 糖尿病及び関連疾患状態を治療する方法
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
JP4427825B2 (ja) 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CN1543451A (zh) 2001-06-07 2004-11-03 过氧化物酶体增生剂激活的受体的调节剂
HUP0401575A2 (hu) 2001-07-30 2004-11-29 Novo Nordisk A/S Új vinil-karbonsav-származékok és ezek alkalmazása cukorbetegség ellen és ezeket tartalmazó gyógyszerkészítmények
ATE526319T1 (de) 2001-08-10 2011-10-15 Nippon Chemiphar Co Aktivator für den peroxisome proliferator- responsiven rezeptor delta
BRPI0213243B8 (pt) 2001-10-12 2021-05-25 Nippon Chemiphar Co composto heterocíclico aromático contendo um anel oxazol, tiazol ou imidazol, ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション ｈＰＰＡＲ活性化剤
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
WO2004022533A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
CA2503276A1 (en) * 2002-10-28 2004-05-06 Novo Nordisk A/S Novel compounds useful in treating ppar mediated diseases
AU2003273783C1 (en) * 2002-10-28 2010-08-12 Vtv Therapeutics Llc Novel compounds and their use as PPAR-modulators
WO2004074439A2 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子
AU2004285849B2 (en) 2003-09-19 2011-04-28 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1670744B9 (en) 2003-09-19 2012-09-05 Janssen Pharmaceutica NV 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs
ATE362367T1 (de) 2003-10-31 2007-06-15 Janssen Pharmaceutica Nv Phenoxyessigsäure-derivate als peroxisom- proliferator-aktivierte rezeptor (ppar) dual- agonisten
TW200538118A (en) 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
MX2007000199A (es) 2004-07-01 2007-03-15 Hoffmann La Roche Derivados de fenilo que comprenden un grupo acetileno.
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
AR058044A1 (es) 2008-01-23
WO2007033231A3 (en) 2007-10-11
CN101304656B (zh) 2013-03-13
BRPI0615835B1 (pt) 2020-04-22
TWI414510B (zh) 2013-11-11
KR20080046695A (ko) 2008-05-27
LTC1937065I2 (Direct) 2025-12-29
ES2535427T3 (es) 2015-05-11
LTPA2025530I1 (Direct) 2025-08-25
US7709682B2 (en) 2010-05-04
EP1937065B1 (en) 2015-01-28
US20070060649A1 (en) 2007-03-15
NZ566504A (en) 2010-11-26
PT1937065E (pt) 2015-03-04
WO2007033231A2 (en) 2007-03-22
DK1937065T3 (en) 2015-02-09
PL1937065T3 (pl) 2015-07-31
FIC20253005I1 (fi) 2025-07-31
CN101304656A (zh) 2008-11-12
AU2006291006B2 (en) 2012-09-13
BRPI0615835A2 (pt) 2011-05-31
KR20150013952A (ko) 2015-02-05
EP1937065A2 (en) 2008-07-02
US20110105616A1 (en) 2011-05-05
KR20160079129A (ko) 2016-07-05
CA2622722C (en) 2016-04-19
KR20130100800A (ko) 2013-09-11
HK1122699A1 (en) 2009-05-29
PE20070434A1 (es) 2007-05-14
UY29791A1 (es) 2006-12-29
KR20180079468A (ko) 2018-07-10
HUS2500034I1 (hu) 2025-09-28
SI1937065T1 (sl) 2015-05-29
JO3006B1 (ar) 2016-09-05
JP5467770B2 (ja) 2014-04-09
AU2006291006A1 (en) 2007-03-22
GT200600420A (es) 2007-05-08
TW200804256A (en) 2008-01-16
US8669288B2 (en) 2014-03-11
CA2622722A1 (en) 2007-03-22
FR25C1030I1 (fr) 2025-09-26
BE2025C533I2 (Direct) 2026-02-02
JP2009514797A (ja) 2009-04-09
FR25C1030I2 (fr) 2026-02-06
HUE025185T2 (en) 2016-02-29
EP1937065A4 (en) 2010-07-21
HN2006032171A (es) 2011-03-15
BRPI0615835B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NL301339I2 (nl) L-lysinezout van seladelpar, in het bijzonder seladelpar-L-lysinedihydraat
NL300885I2 (nl) Irinotecansucrosofaatzout
DK2046826T3 (da) Exendin-fusionsproteiner
DK3118220T3 (da) Protein
DK1767815T3 (da) Reduktionsgear
BRPI0814971A2 (pt) Proteína
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
EP1903334A4 (en) BIOSENSOR
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
EP1909098A4 (en) BIOSENSOR
DE602006019800D1 (de) Paniermaschine
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
DE602006009980D1 (de) Biosensor
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
BRPI0814800A2 (pt) Derivados de aminoácidos
DK1971588T3 (da) Tiglien-3-onderivater
EP1852499A4 (en) NEUROTISATIONSFÖRDERNDES AGENS
EP1968576A4 (en) MIF INHIBITORS
NL1031705A1 (nl) Aminozuurderivaten.
ATE488493T1 (de) Biphenyl- und naphthylphenylhydroxamsäurederivate
ATE541837T1 (de) Oxaphenanthren-derivate
DE502006007983D1 (de) Rettungsweste
DK2219663T3 (da) Revers-protein
ITPD20050023U1 (it) Impedenzimetro corporeo